Research on discovering and developing new drugs. Covers structure-revealing tools, eye-disease mechanisms, protein screening, and once-daily oral medicines.
A team from Tokyo University of Science developed a novel trivalent platform for triple click chemistry, allowing for the efficient synthesis of complex compounds. The approach utilizes simple initial materials and promotes sustainable pharmaceutical synthesis.
A new method allows for accurate measurement of blood-brain barrier permeability, revealing that many CNS drugs penetrate the barrier rapidly. The study found that plasma proteins play a crucial role in maintaining brain delivery of lipophilic agents.
A new study published in the Journal of Crohn's and Colitis reveals that vancomycin may be an effective treatment for people with inflammatory bowel disease (IBD) and autoimmune liver disease. The antibiotic achieved clinical remission in 80% of patients, with significant decreases in inflammatory markers and mucosal healing.
A new 3D bioprinted gastric cancer model successfully replicates the unique characteristics of individual patients' tissues, predicting drug responses and prognosis with high accuracy. This innovative platform enables rapid evaluation within two weeks, contributing to personalized cancer treatment development.
The Terasaki Institute for Biomedical Innovation has announced the recipients of its inaugural Keith Terasaki Mid-Career Innovation Award. Dr. Liangfang Zhang and Dr. Aydogan Ozcan were recognized for their innovative approaches to translating groundbreaking research into real-world impact.
A new study identified USP5 as an enzyme crucial for breaking down unneeded or damaged proteins in the heart. Low levels of USP5 lead to protein buildup, triggering dilated cardiomyopathy in animal models. Increasing USP5 levels helps clear protein 'junk', improving heart function and reducing disease progression.
A new drug developed by the Centre for Addiction and Mental Health (CAMH) has shown significant promise in reversing memory loss in a mouse model of Alzheimer's disease. The drug, GL-II-73, selectively targets GABA receptors to restore brain function and repair damaged neural connections.
Daniel Armstrong, a renowned UTA chemist, has been honored with the prestigious 2025 Pittcon Analytical Chemistry Award for his pioneering work in analytical chemistry. His research focuses on developing new approaches to identify chiral disease biomarkers, peptide epimers, and isotopic compounds.
A team of researchers has developed a novel model of the Blood-Brain Barrier, which mimics the complex structure of cerebral blood vessels. This breakthrough enables scientists to study neuroinflammation and develop new therapeutic strategies for Alzheimer's disease and other neurodegenerative disorders.
Researchers at Lancaster University have developed a new method to detect Alzheimer's disease by analyzing changes in brain oxygenation dynamics and neuronal function. The study found that individuals with Alzheimer's disease exhibit altered respiratory frequency, which may be an early indicator of the condition.
A UT Health San Antonio researcher and her biotechnology company partner with the school to develop a breakthrough oral cancer drug, CIDD99. The partnership aims to create effective, less toxic cancer therapies for aggressive cancer types.
A new study suggests that women at risk of postpartum depression may have characteristic levels of neuroactive steroids in their blood during pregnancy. Elevated progesterone levels and imbalances in its metabolism may be associated with an increased risk of PPD.
Scientists at Tel Aviv University successfully transport mRNA-based drugs to the immune system of small and large intestines without passing through the liver. The breakthrough could enable treatments for inflammatory diseases such as Crohn's and colitis.
Southwest Research Institute's Risk Evaluation & Medical Decision Efficacy (REMEDY) tool supports agile medical decisions on countermeasures for chemical and biological threats. The REMEDY mission risk evaluations quantify risks and benefits of medical countermeasures, enabling operational planners to make informed decisions.
Researchers identified a potential new treatment for aggressive sarcoma arising in nerves, using a pre-clinical platform that combines inhibitors targeting specific mutations. The triple combination of MEKi-BETi-CDKi showed promising results in shrinking tumors and even eliminating some cases, offering hope for improved treatment options.
A review of cell death and aging in cancer research reveals the significance of cellular senescence in promoting cancer growth. The study highlights the potential of various types of programmed cell death, such as necroptosis and pyroptosis, as therapeutic targets against senescent cells.
Researchers developed AshPhos, a ligand that facilitates the formation of carbon-nitrogen bonds using inexpensive materials. The tool has potential applications in pharmaceuticals, nanomaterials, and degrading PFAS pollutants.
A study found that people with delayed REM sleep have higher levels of toxic proteins amyloid and tau, and lower levels of healthy protein BDNF, which can increase the risk of developing Alzheimer's. Practicing healthy sleep habits may help mitigate this risk.
A West Virginia University legal scholar argues that current laws favor biologic drugs with longer exclusivity periods, affecting their pricing. The scholar suggests reducing exclusivity for biologics to bring them in line with small-molecule drugs, which could lower drug costs.
A retrospective cohort study of 44,000 individuals found associations between baseline fasting glucose levels, age, sex, and body mass index with the development of diabetes. The study highlights individual variation in diabetes risk according to commonly measured clinical variables, suggesting potential for targeted interventions.
A team from Osaka Metropolitan University has developed a crystal patterning method that controls the position and orientation of photochromic crystals, known as diarylethenes. This breakthrough allows for the creation of convex structures with precise control over crystal shape and size.
Researchers developed guidelines to compare lab experiments, molecular simulations, and AI for drug delivery testing. The new framework aims to improve the accuracy of permeability testing and accelerate the development of life-saving drugs.
A recent study found that long COVID is more prevalent in women than men, and the association was linked to factors such as age, pregnancy, and menopausal status. The research highlights the need for targeted drug development and improved management strategies for long COVID.
PolyU's 16 projects funded by HMRF focus on healthcare innovation, covering areas like nursing care, health tech, and biomedical engineering. The research aims to address global healthcare challenges and improve overall well-being.
Researchers at UMass Amherst have developed a non-toxic bacterial therapy, BacID, to deliver cancer-fighting drugs directly into tumors. The therapy uses genetically engineered strains of Salmonella that can target tumors and control the release of cancer-fighting drugs inside cancer cells.
A multidisciplinary team led by the Wyss Institute aims to create novel anesthesia-inducing drugs that can safely induce an anesthesia-like state without compromising vital functions. The project leverages expertise from Harvard's MCB, MIT, and Tufts University to develop safe battlefield-ready anesthetics.
A recent NUS Medicine study found that a molecule called DUSP6 plays a major role in helping colorectal cancer grow, with higher levels linked to poorer prognosis and decreased survival. Researchers suggest blocking DUSP6 could lead to new therapies for CRC treatment.
A new strategy enhances pharmaceutical production in Chinese hamster ovary cells by knocking out a gene circuit responsible for producing lactic acid. The approach improves growth rates and significantly increases protein yield, overcoming a decades-old challenge in biomanufacturing.
Researchers discovered that the protein PIN1 drives bladder cancer by triggering cholesterol synthesis, which fuels out-of-control cell growth. A combination of statins and a PIN1 inhibitor effectively blocks tumor growth in mice, offering a promising therapeutic approach for this deadly disease.
Researchers use SCP-Nano to analyze distribution of extremely low doses of nanocarriers throughout the mouse body, visualizing each cell that has taken them up. The platform identifies unwanted accumulation in organs like the heart and liver, paving the way for safer mRNA therapeutics.
Researchers developed a predictive tool using the Florey Dementia Index to forecast onset ages of mild cognitive impairment and Alzheimer's. The validated tool may help prioritize patients for disease-modifying treatments.
A new RAND study found that the median cost of developing a new drug is $150 million, while the mean cost is $369 million. Excluding high-cost outliers, the average cost drops to $950 million. The study suggests using median costs for policy discussions about pharmaceutical research and development.
A recent case series suggests that an extended course of Paxlovid may help some patients with long Covid experience sustained improvements in their symptoms. The study, published in Communications Medicine, found that five out of 13 patients experienced significant symptom relief after taking the antiviral drug for 15 days.
Researchers have developed a new quantum sensing technology that can detect individual nuclei, revealing tiny differences in molecular structure and dynamics. This unprecedented sensitivity enables scientists to study the building blocks of nature at an entirely new scale, leading to breakthroughs in fields like drug development.
Organoids, derived from stem cells, closely mimic human tissue for biomedical research and drug testing. Standardization is crucial for generating reliable results in organoid construction, requiring approved operating procedures and informed consent from donors.
Researchers found significant functional variations between rodent and human PD-1 due to evolutionary divergence. The study reveals a unique motif present in most mammals but missing in rodents, leading to uniquely weaker rodent PD-1.
Researchers at Rice University have created a sustainable way to integrate chlorine into chemical building blocks, reducing costs and environmental impact. The new process uses iron and sulfur catalysts activated by mild blue light, eliminating harsh chemicals and high temperatures.
Researchers found that bumetanide treatment normalizes neonatal social communication in newborn pups with the fragile X mutation, but reduces post-pubertal social interaction. The study suggests stage-specific effects on social development and raises questions about timing and dosing of bumetanide for targeted interventions.
Researchers have unveiled a critical mechanism linking cellular stress in the brain to Alzheimer's disease progression, highlighting microglia as central players in both protective and harmful responses. The study reveals that blocking a specific stress pathway reverses symptoms of Alzheimer's disease in preclinical models.
A new study published in Neurology suggests that the recently approved drug atogepant can start working to prevent migraines as early as the first day of treatment. The study, which focused on three trials over 12 weeks, found significant reductions in migraine frequency and severity among participants taking the drug.
A UC Riverside-led team, funded by the NIH, aims to uncover molecular factors governing gene regulation and chromatin organization in P. falciparum. The project focuses on long non-coding RNAs, which play a crucial role in regulating gene expression and influencing disease progression.
Researchers create SciAgents framework to autonomously generate and evaluate promising research hypotheses in biologically inspired materials. The framework uses graph reasoning methods to organize relationships between scientific concepts, mimicking biological systems.
Nearly 50 ISS National Lab-sponsored payloads splashed down safely on SpaceX’s CRS-31 mission, including research for early cancer detection and neurodegenerative conditions treatments. The investigations leveraged the space station's unique environment to improve life on Earth.
A phase 1/2 clinical trial has demonstrated the safety and effectiveness of the AEF0217 molecule in improving cognitive function in people with Down syndrome. Measured outcomes showed significant improvements in behavioral skills, social interactions, and cognitive flexibility.
Scientists at the University of Plymouth are creating a humanised meningioma model to study interactions between immune cells and tumour cells, enabling the development of effective therapies for NF2-related schwannomatosis. The model will be made available worldwide to test new treatments and reduce clinical trial delays.
A novel radiotracer has accurately identified a crucial cancer biomarker, Trop2, found in various types of cancer. The radiotracer, <sup>18</sup> F-AlF-RESCA-T4, enables precise visualization of Trop2 expression and can differentiate lung inflammation from cancer.
Researchers at MIT have developed Boltz-1, an open-source AI model that achieves state-of-the-art performance in predicting biomolecular structures. The model surpasses AlphaFold3, which is limited to academic research and commercial use, by incorporating new algorithms and improving prediction efficiency.
A team of University of Melbourne researchers has developed a novel drug delivery system composed of metal-biomolecule networks (MBNs), which eliminate the need for toxic drug carriers. The MBNs show antiviral, antibacterial, antifungal, anti-inflammatory and anti-cancer properties, potentially increasing success in drug development.
Researchers at UW-Madison found two microbial bile acids that affect colon cancer risk in opposite ways, with one slowing growth and the other fueling tumors. The study provides a roadmap for new cancer detection methods and treatments.
Researchers investigate how perturbed gene expression contributes to neurodegenerative disorders like Alzheimer's. Alternative polyadenylation, a mechanism regulating protein production, is being studied for its potential role in the disease.
Researchers at TUM have grown tumor organoids that reproduce the morphological complexity of pancreatic cancer cells in the laboratory. The team used machine learning to categorize the organoids into different phenotypes based on their appearance and behavior, which react differently to treatments.
A team of researchers has identified an 18-digit code within a protein called Wnt7a that allows it to attach itself to exosomes, enabling targeted delivery of proteins throughout the body. This discovery has major implications for the development of new therapies for diseases such as Duchenne muscular dystrophy.
A new review published in Blood Cancer Discovery outlines how research supported a recent FDA committee decision to allow minimal residual disease as an endpoint for accelerated approval in multiple myeloma. This decision could cut a decade off the drug development process, enabling faster innovation in cancer treatment.
Researchers combine a precision cancer drug with an antibody and radiation therapy to eliminate tumors without causing side effects. The approach uses the cancer drug as a molecular flag for cancerous cells, allowing immune cells to target them. This method has shown promise in eliminating lung cancer in mice with minimal side effects.
Scientists identify hederagenin, a highly selective antagonist of NPFFR1, to block chronic pain. The discovery could facilitate the rational design of future therapeutics for pain management.
Researchers identified the critical role of TIMM50 protein in mitochondrial energy production and its link to a severe and rare neurological disease. The study's findings suggest potential targets for future drug treatments and advance research on protein import into mitochondria in brain cells.
Researchers developed a deep-learning model to predict organoid development at an early stage, outperforming human experts in accuracy and speed. The model classifies bright-field images of organoids into three quality categories, indicating their potential for regenerative medicine applications.
Researchers at Tokyo University of Science have developed a new, highly selective and efficient method for synthesizing anti-cancer compounds. The innovative approach uses isopropyl magnesium bromide as a base to improve selectivity and scalability.
A new Simon Fraser University study finds that antidepressants are associated with reduced genital sensitivity in 13% of users, compared to 1% of other psychiatric medication users. The study highlights the need for better patient education and warnings about potential side effects.
A new study has solved a years-old mystery about which patients with aggressive breast cancer are helped by a targeted cancer treatment. The researchers found that low levels of the protein IGFBP7 can predict which patients will benefit from the treatment, providing hope for its continued development.